WO2000071148A3 - Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin - Google Patents

Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin Download PDF

Info

Publication number
WO2000071148A3
WO2000071148A3 PCT/US2000/014311 US0014311W WO0071148A3 WO 2000071148 A3 WO2000071148 A3 WO 2000071148A3 US 0014311 W US0014311 W US 0014311W WO 0071148 A3 WO0071148 A3 WO 0071148A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
activity
smooth muscle
agents
modulate
Prior art date
Application number
PCT/US2000/014311
Other languages
French (fr)
Other versions
WO2000071148A2 (en
Inventor
Myron Spector
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Priority to EP00937734A priority Critical patent/EP1180037A2/en
Priority to JP2000619450A priority patent/JP2003500113A/en
Priority to CA002374301A priority patent/CA2374301A1/en
Publication of WO2000071148A2 publication Critical patent/WO2000071148A2/en
Publication of WO2000071148A3 publication Critical patent/WO2000071148A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/386—Ligaments, tendons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention is directed to therapeutic methods that are based upon an ability to modulate cellular contraction. This is accomplished by administering agents that either inhibit or induce the activity of alpha-smooth muscle actin.
PCT/US2000/014311 1999-05-26 2000-05-25 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin WO2000071148A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00937734A EP1180037A2 (en) 1999-05-26 2000-05-25 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
JP2000619450A JP2003500113A (en) 1999-05-26 2000-05-25 Therapeutic use of drugs that modulate alpha smooth muscle actin activity
CA002374301A CA2374301A1 (en) 1999-05-26 2000-05-25 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13623599P 1999-05-26 1999-05-26
US60/136,235 1999-05-26

Publications (2)

Publication Number Publication Date
WO2000071148A2 WO2000071148A2 (en) 2000-11-30
WO2000071148A3 true WO2000071148A3 (en) 2001-09-27

Family

ID=22471961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014311 WO2000071148A2 (en) 1999-05-26 2000-05-25 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin

Country Status (4)

Country Link
EP (1) EP1180037A2 (en)
JP (2) JP2003500113A (en)
CA (1) CA2374301A1 (en)
WO (1) WO2000071148A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063301A1 (en) * 2003-12-26 2005-07-14 Toshio Hirano Emt inducer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428010A (en) * 1984-10-12 1995-06-27 Zymogenetics, Inc. Biologically active B-chain homodimers
WO1995028950A1 (en) * 1994-04-20 1995-11-02 Institute Of Molecular Biology, Inc. Administration of platelet-derived growth factor and bone seeking drugs for osteoporosis and bone regeneration
WO1997007136A2 (en) * 1995-08-18 1997-02-27 The Victoria University Of Manchester Pharmaceutical composition containing inhibitors of interferon-gamma
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
WO1997041886A1 (en) * 1996-05-09 1997-11-13 Pharma Pacific Pty. Ltd. Stimulation of host defence mechanisms against tumors
US5902741A (en) * 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
US5200177A (en) * 1989-12-01 1993-04-06 The Children's Medical Center Corporation Treatment of atopic disorders with gamma-interferon
WO1995026761A1 (en) * 1994-04-04 1995-10-12 Collagen Corporation Cell-gels
DE69531638T2 (en) * 1994-06-06 2004-06-17 Osiris Therapeutics, Inc. BIOMATRIX FOR TISSUE REGENATION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5428010A (en) * 1984-10-12 1995-06-27 Zymogenetics, Inc. Biologically active B-chain homodimers
US5902741A (en) * 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
WO1995028950A1 (en) * 1994-04-20 1995-11-02 Institute Of Molecular Biology, Inc. Administration of platelet-derived growth factor and bone seeking drugs for osteoporosis and bone regeneration
WO1997007136A2 (en) * 1995-08-18 1997-02-27 The Victoria University Of Manchester Pharmaceutical composition containing inhibitors of interferon-gamma
WO1997041886A1 (en) * 1996-05-09 1997-11-13 Pharma Pacific Pty. Ltd. Stimulation of host defence mechanisms against tumors

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
COMUT A A ET AL: "Association of fibroblast orientation around titanium in vitro with expression of a muscle actin", BIOMATERIALS, vol. 21, no. 18, September 2000 (2000-09-01), pages 1887 - 1896, XP004207023 *
DENNISON D K ET AL: "Differential effect of TGF-beta-1 and PDGF on proliferation of periodontal ligament cells and gingival fibroblasts.", JOURNAL OF PERIODONTOLOGY, vol. 65, no. 7, 1994, pages 641 - 648, XP000971595 *
DESROSIERS E A ET AL: "Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 14, no. 2, March 1996 (1996-03-01), pages 200 - 208, XP000971598 *
LIND M: "Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation.", ACTA ORTHOPAEDICA SCANDINAVICA, no. suppl. 283, October 1998 (1998-10-01), pages 1 - 37, XP000971632 *
MASUR S K ET AL: "Myofibroblasts differentiate from fibroblasts when plated at low density.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 9, April 1996 (1996-04-01), pages 4219 - 4223, XP002156190 *
MENARD C ET AL: "Contractile behavior of smooth muscle actin-containing osteoblasts in collagen-GAG matrices in vitro: implant-related cell contraction", BIOMATERIALS, vol. 21, no. 18, September 2000 (2000-09-01), pages 1867 - 1877, XP004207021 *
MUELLER S M ET AL: "alpha-Smooth muscle actin and contractile behavior of bovine meniscus cells seeded in type I and type II collagen-GAG matrices.", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 45, no. 3, 5 June 1999 (1999-06-05), pages 157 - 166, XP000971452 *
MUELLER S M ET AL: "Meniscus cells seeded in type I and type II collagen-GAG matrices in vitro.", BIOMATERIALS, vol. 20, no. 8, April 1999 (1999-04-01), pages 701 - 709, XP002156186 *
MURRAY M M ET AL: "Fibroblast distribution in the anteromedial bundle of the human anterior cruciate ligament: The presence of alpha-smooth muscle actin-positive cells.", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 17, no. 1, January 1999 (1999-01-01), pages 18 - 27, XP000971445 *
SCHNEIDER T O ET AL: "Expression of alpha-smooth muscle actin in canine intervertebral disc cells in situ and in collagen-glycosaminoglycan matrices in vitro.", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 17, no. 2, March 1999 (1999-03-01), pages 192 - 199, XP000971444 *
SCHULZ TORRES D M ET AL: "Tendon cell contraction of collagen-GAG matrices in vitro: effect of cross-linking", BIOMATERIALS, vol. 21, no. 15, August 2000 (2000-08-01), pages 1607 - 1619, XP004204635 *
WOO S L-Y ET AL: "Engineering the healing of the rabbit medial collateral ligament.", MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING, vol. 36, no. 3, May 1998 (1998-05-01), pages 359 - 364, XP000971583 *
YOKOZEKI M ET AL: "Interferon-gamma inhibits the myofibroblastic phenotype of rat palatal fibroblasts induced by transforming growth factor-beta1 in vitro.", FEBS LETTERS, vol. 442, no. 1, 8 January 1999 (1999-01-08), pages 61 - 64, XP002156189 *

Also Published As

Publication number Publication date
JP2004167270A (en) 2004-06-17
JP2003500113A (en) 2003-01-07
CA2374301A1 (en) 2000-11-30
EP1180037A2 (en) 2002-02-20
WO2000071148A2 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
TW200635588A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
MXPA04004966A (en) 3-beta-D-RIBOFURANOSYLTHIAZOLO[4,5-d.
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
ES2191152T3 (en) COMBINED THERAPY FOR THE TREATMENT OF PSYCHOSIS.
PL332432A1 (en) Oxadiazoles, method of obtaining them as well as their application as therapeutic agents
TR200101895T2 (en) Treatment of sexual ailments.
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
WO2000018439A3 (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
TR200800693T2 (en) Treatment of myelin-losing diseases or conditions
HK1028197A1 (en) Combination therapy for modulating the human sexual response
AU4726797A (en) Prophylactic/remedial agent
WO1998046632A3 (en) Inhibitors for urokinase receptor
WO2000071148A3 (en) Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
AU7652400A (en) Novel combination for the treatment of sexual dysfunction
WO2003020221A3 (en) Method of treating cancerous disease
IT1285754B1 (en) EQUIPMENT FOR THE AESTHETIC TREATMENT OF PARTS OF THE HUMAN BODY
MX9204528A (en) 0ALL TO TREAT PREMENSTRUAL SYNDROME THROUGH ADMINISTRATION OF AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR.
WO2001089510A3 (en) Use of an ampa receptor potentiator for the treatment of obesity
WO2000031100A3 (en) Benzylmaltosides as inhibitors of smooth muscle cell proliferation
ES2167942T3 (en) EMPLOYMENT OF 2-6-AMINOTETRALINES APPROPRIATE SUBSTITUTES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE THERAPEUTIC TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE PATHOLOGIES.
AUPR951101A0 (en) Method of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000937734

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2374301

Country of ref document: CA

Ref country code: CA

Ref document number: 2374301

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 619450

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000937734

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000937734

Country of ref document: EP